|
06 Sep 2025 |
Natco Pharma
|
Consensus Share Price Target
|
852.75 |
982.64 |
- |
15.23 |
hold
|
|
|
|
|
09 Aug 2017
|
Natco Pharma
|
ICICI Securities Limited
|
852.75
|
955.00
|
830.60
(2.67%)
|
Target met |
Hold
|
|
|
EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to | 137 crore (I-direct estimate: | 109 crore) Adjusted net profit increased 96% YoY to | 93 crore (I-direct...
|
|
08 Aug 2017
|
Natco Pharma
|
HDFC Securities
|
852.75
|
|
925.25
(-7.84%)
|
|
Results Update
|
|
|
Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter.
|
|
09 Jun 2017
|
Natco Pharma
|
Edelweiss
|
852.75
|
1213.00
|
1072.30
(-20.47%)
|
|
Buy
|
|
|
Natco Pharmaceuticals Ltd (NPL) continues to deliver on near-term expectations while simultaneously building up pipeline for a sustainable future growth.
|
|
07 Jun 2017
|
Natco Pharma
|
Axis Direct
|
852.75
|
1030.00
|
995.35
(-14.33%)
|
Target met |
Buy
|
|
|
Higher gTamiflu profit share (increased market share and stronger flu season) pushed Q4FY17 EBITDA to Rs 2.4bn, up 159% YoY and 22% above our estimate (despite Rs 600mn one-time expense).
|
|
01 Jun 2017
|
Natco Pharma
|
Edelweiss
|
852.75
|
1027.00
|
943.70
(-9.64%)
|
Target met |
Buy
|
|
|
Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 577 crs, which was 5% higher than our estimates of INR 550 crs. The strong uptick in numbers was primarily on account of profit...
|
|
31 May 2017
|
Natco Pharma
|
ICICI Securities Limited
|
852.75
|
1055.00
|
933.65
(-8.66%)
|
Target met |
Buy
|
|
|
EBITDA margins improved 1810 bps YoY to 41.7% (I-direct estimates: 38.5%) mainly due to Oseltamivir exclusivity. EBITDA grew 159% to | 241 crore (I-direct estimate: | 215 crore) Adjusted net profit increased 178% YoY to | 177 crore (I-direct...
|
|
23 Mar 2017
|
Natco Pharma
|
Edelweiss
|
852.75
|
995.00
|
790.10
(7.93%)
|
Target met |
Buy
|
|
|
Natco Pharmaceuticals (Natco) is a R&D focused player with strong focus on oncology and hepatology. The company is a market leader in the domestic generic oncology space with 23% market share.
|
|
09 Mar 2017
|
Natco Pharma
|
Angel Broking
|
852.75
|
926.00
|
782.40
(8.99%)
|
Target met |
Buy
|
|
|
Natco Pharma is a Hyderabad based pharma company with focus on limited competition and high margin products. It has presence in domestic and global markets and has two main business segments i.e. API and Formulations. Natco's topline and bottomline is set to grow at 36% and 61% CAGR over FY16-FY19E due to 1) strong performance of domestic..
|
|
17 Feb 2017
|
Natco Pharma
|
HDFC Securities
|
852.75
|
|
762.35
(11.86%)
|
|
Results Update
|
|
|
Revenue rose by 54.83% to Rs. 642.86 Cr in Q3FY17 when compared to the previous quarter. Also, it grew by 133.62% when compared with Q3FY16.
|
|
16 Feb 2017
|
Natco Pharma
|
Edelweiss
|
852.75
|
995.00
|
766.45
(11.26%)
|
Target met |
Buy
|
|
|
Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 679 crs, which was 55% higher than our estimates of INR 321 crs. The strong uptick in numbers was primarily on account of...
|